Singapore, 18 April 2024— Horizon Quantum Computing, a company building software development tools for quantum computers, today announced that it is establishing a first-of-a-kind testbed for integrating quantum computing hardware with...
Syndax is a late stage oncology company whose lead product candidate is entinostat, an oral, selective histone deacetylase inhibitor (HDACi) that is being developed to treat therapy-resistant cancers through an epigenetic mechanism. Entinostat was recently granted Breakthrough Therapy designation by the FDA based on data from the company's completed Phase 2b clinical trial for ER+ metastatic breast cancer.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.